Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | GFER | P55789 | 2/20 | 0.32 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564090 | 0.97 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2NPSR1CYP2C9POLB | |
| SCHEMBL3557598 | 0.95 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2NPSR1CYP2C9POLB | |
| SCHEMBL13117104 | 0.94 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2NPSR1CYP2C9POLB | |
| SCHEMBL3561231 | 0.89 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2NPSR1CYP2C9TSHR | |
| SCHEMBL13139654 | 0.89 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2NPSR1CYP2C9TSHR | |
| SCHEMBL3563534 | 0.87 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2NPSR1CYP2C9POLB | |
| SCHEMBL13117101 | 0.87 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2NPSR1CYP2C9POLB | |
| SCHEMBL13117094 | 0.87 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2NPSR1CYP2C9TACR3 | |
| SCHEMBL13117325 | 0.87 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2NPSR1CYP2C9POLB | |
| SCHEMBL13117096 | 0.86 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2NPSR1CYP2C9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010525-B1 | Diketo-piperazine and piperidine derivatives as antiviral agents | BRISTOL MYERS SQUIBB CO (US) | 2013-08-28 | — | — | EP | disclosed |
| EP-2010525-B1 | Diketo-piperazine and piperidine derivatives as antiviral agents | BRISTOL MYERS SQUIBB CO (US) | 2013-08-28 | — | — | EP | disclosed |
| US-7807676-B2 | Diketo-Piperazine and Piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807676-B2 | Diketo-Piperazine and Piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807676-B2 | Diketo-Piperazine and Piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807671-B2 | Diketo-piperazine and piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807671-B2 | Diketo-piperazine and piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-20070249579-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| US-20070249579-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139572-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | EIF2AK2, DCK, MAVS | ALDH1A1 1424/4885SMN1; SMN2 3945/4885NPSR1 2908/4885 |
| US-20070249579-A1 | DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | EIF2AK2, DCK, MAVS | ALDH1A1 1424/4885SMN1; SMN2 3945/4885NPSR1 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.